Preliminary Results Date

RNS Number : 4173P

Epistem Holdings plc

01 October 2013

 



Preliminary Results Date

1^st October 2013

Epistem Holdings Plc (LSE: EHP), the biotechnology and personalised medicine company will be announcing its preliminary results for the year ended 30 June 2013 on Tuesday, 22 October 2013.

An analysts' meeting will be held at the London Stock Exchange, 10 Paternoster Square, London EC4M 7LS in Forum 3 at 9.30am. Due to the security measures in place at the LSE, please ensure you arrive at 9am for an on time start.

If you would like to attend, please contact either Anna Dunphy or Mike Wort at Walbrook PR.

Epistem Plc
Matthew Walls	Chief Executive Officer	[phone]
John Rylands	Finance Director	[phone]
Peel Hunt LLP
James Steel		[phone]
Vijay Barathan		[phone]
Walbrook PR
Mike Wort / Anna Dunphy		[phone]

Notes to Editors:

About Epistem

Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and pharmacogenomics in the areas of oncology, gastrointestinal, dermatological and infectious disease.

Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.

 

END

 

 

NORLLFIFIVLLIIV